NASDAQ
16.26USD
-0.19 (-1.16%)
We have scored 26 news catalysts on Summit Therapeutics Inc. (SMMT) over the past 12 months. The biggest single-day move next to one of them came Jun 1, 2026, when SMMT closed −10.4%: “Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's”. Coverage across the window leans positive (average ticker sentiment +0.20). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
13B
P/E
—
EPS
—
Beta
-1.24
52W range
12.07-29.23
Day range
16.13–16.74
Open
16.37
Prev close
16.45
Volume
982.9K
Avg volume
5.5M
Dividend
0.00
IPO
2015-03-05
Analysts publish price targets on SMMT, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $11.90 to $38
as of 2026-09-24
The market is 43% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Summit Therapeutics Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SMMT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
The reconstruction
The price sits 43% below the median published target and at the 33rd percentile of the model spread, meaning the market leans bearish and refuses to pay for the full commercial success of ivonescimab that most analysts expect.
What the disagreement turns on
Whether ivonescimab's overall survival and efficacy data will support peak sales that justify the median analyst target, a question that cannot be settled with the currently wired data because consumer attention and unit volumes do not capture clinical trial outcomes.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
